Here, as an alternative to direct targeting of the bone cells, we propose an innovative strategy to bypass bone targeting by using liver as a biofactory to secrete a negative regulator of the FGF23 signaling pathway and reduce phosphate wasting, the main cause of poor bone mineralization in XLH. The gene discussed is FGF23; the disease is X-linked hypophosphatemia.